fluorouracil has been researched along with celecoxib in 66 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 38 (57.58) | 29.6817 |
| 2010's | 26 (39.39) | 24.3611 |
| 2020's | 2 (3.03) | 2.80 |
| Authors | Studies |
|---|---|
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Bensdorf, K; Guo, C; Gust, R; Huang, W; Liu, H; Liu, W; Qian, H; Rubner, G; Wang, Y; Wellner, A; Zhang, H; Zhang, Y; Zhou, J | 1 |
| Duan, YC; Lin, ZT; Liu, GZ; Liu, HM; Wang, P; Xu, HW; Zheng, JX | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Ji, Y; Ju, L; Lu, X; Wu, K; Yang, H; Yu, M | 1 |
| Cai, H; Huang, X; Huang, Y; Jiang, B; Jiang, J; Shen, H; Sun, Y; Wu, X; Xu, J; Xu, S; Yao, H; Zhang, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bernardino, AMR; Boechat, N; Dos Santos, MS; Faria, JV; Miguita, AGC; Vegi, PF | 1 |
| Akber Ansari, S; Arote, R; Chhajed, S; Pathan, SK; Patil, R; Sangshetti, J; Shinde, DB | 1 |
| Abd El Wahab, SM; Alaaeddine, R; Allam, RM; Angeli, A; Belal, ASF; Daabees, H; Eid, AH; El-Hawash, SA; El-Yazbi, AF; Elagawany, M; Elzahhar, PA; Hegazy, RR; Helmy, MW; Supuran, CT | 1 |
| Rich, T | 1 |
| Ayers, GD; Lin, E; Morris, JS | 1 |
| Hashitani, S; Maeda, T; Nishimura, N; Noguchi, K; Sakurai, K; Takaoka, K; Urade, M | 1 |
| Rich, TA; Shepard, R | 1 |
| Fuchs, CS | 1 |
| Breza, TS; Oberyszyn, TM; Tober, KL; Wilgus, TA | 1 |
| Bria, E; Carlini, P; Cognetti, F; Di Cosimo, S; Gelibter, A; Malaguti, P; Milella, M; Pellicciotta, M; Ruggeri, EM; Terzoli, E | 1 |
| Berman, B; Ramirez, CC; Villa, AM | 1 |
| Ansari, R; Fineberg, N; Fox, E; Govindan, R; Hanna, N; Helft, P; Kesler, K; Mantravadi, P; McLeod, H; Stoner, C | 1 |
| Blanke, CD; Deloughery, TG; Koop, DR; Mattek, NC | 1 |
| Flinner, R; Forbes, A; Fuhrman, C; Gaffney, DK; Greven, K; Kerlin, K; Nichols, RC; Ryu, J; Winter, K; Zempolich, K | 1 |
| Borsellino, N; Cartenì, G; Colucci, G; Gebbia, N; Gebbia, V; Giuliani, F; Lopez, M; Maiello, E; Manzione, L; Paoletti, G; Pezzella, G; Romito, S | 1 |
| Ansari, R; Cheng, L; Helft, P; Juliar, B; Loehrer, P; Pan, CX; Pletcher, W; Seitz, D; Sweeney, C; Vinson, J | 1 |
| Blanquicett, C; Buchsbaum, DJ; Carpenter, MD; Chhieng, DC; Diasio, RB; Eloubeidi, M; Johnson, MR; Russo, S; Saif, MW; Sellers, JC; Vickers, SM | 1 |
| Chow, LW; Loo, WT; Lui, EL; Toi, M; Wai, CC; Zhu, L | 1 |
| Ayers, GD; Brown, T; Crane, CC; Curley, SA; Delcos, M; Feig, B; Janjan, N; Lin, EH; Morris, J; Rodriguez-Bigas, MA; Ross, A; Skibber, J; Vadhan, SR | 1 |
| Colucci, G; Di Renzo, N; Gebbia, V; Giuliani, F; Lopez, M; Maiello, E; Mallamaci, R; Pezzella, G; Romito, S | 1 |
| Chow, LW; Toi, M; Ueno, T | 1 |
| Debucquoy, A; Geboes, K; Goethals, L; Haustermans, K; Mc Bride, WH; Roels, S | 1 |
| André, T; Bidard, FC; de Gramont, A; Fellague-Chebra, R; Flesch, M; Hebbar, M; Louvet, C; Mabro, M; Mineur, L; Postel Vinay, S; Tournigand, C | 1 |
| Biagi, J; Dawson, SJ; Foo, KF; Hui, A; Jefford, M; Leong, T; Michael, M; Milner, AD; Ngan, SY; Thomas, RJ; Zalcberg, JR | 1 |
| Avizonis, V; Dicker, AP; Eifel, PJ; Fromm, M; Gaffney, DK; Greven, K; Miller, B; Ryu, J; Winter, K | 1 |
| Cao, S; Creaven, PJ; Durrani, FA; Iyer, RV; Javle, MM; Lawrence, DD; Noel, DC; Pendyala, L; Rustum, YM; Smith, PF | 1 |
| El-Rayes, BF; Ferris, AM; Heilbrun, LK; Manza, SG; Philip, PA; Rusin, B; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM | 1 |
| Egawa, S; Hayashi, N; Iijima, H; Irie, T; Ishii, S; Kakiuchi, Y; Kawano, S; Murata, H; Nishida, T; Shinzaki, S; Takehara, T; Tsuji, S; Tsujii, M; Yasumaru, M; Yoshio, T | 1 |
| Bae, YM; Chun, WJ; Lim, YJ; Rhee, JC | 1 |
| Avizonis, V; Dicker, AP; Eifel, PJ; Fromm, M; Gaffney, DK; Greven, K; Miller, B; Ryu, J; Small, W; Winter, K | 1 |
| Chen, XM; Feng, JX; Wang, YJ; Zhang, X; Zhu, FS | 1 |
| Arends, J; Drevs, J; Frost, A; Häring, B; Hennig, J; Medinger, M; Mross, K; Steinbild, S; Strecker, R; Unger, C | 1 |
| Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ | 1 |
| Carlini, P; Cognetti, F; Fabi, A; Ferretti, G; Gelibter, A; Melucci, E; Metro, G; Milella, M; Mottolese, M; Papaldo, P; Russillo, M; Sperduti, I; Tomao, S | 1 |
| Baron, A; Basche, M; Dancey, J; Eckhardt, SG; Gore, L; Gustafson, DL; Holden, SN; Lam, ET; O'Bryant, CL; Serkova, N | 1 |
| Davies, JM; Goldberg, RM | 1 |
| Bria, E; Carlini, P; Carpanese, L; Cognetti, F; De Marco, S; Gelibter, A; Milella, M; Nuzzo, C; Pino, MS; Ruggeri, EM; Sperduti, I | 1 |
| Barrueco, J; Jackson, NA; Marshall, J; Meyerhardt, J; Mitchell, E; Soufi-Mahjoubi, R; Zhang, X | 1 |
| D'Hoore, A; Debucquoy, A; Geboes, K; Goethals, L; Haustermans, K; Libbrecht, L; McBride, WH; Penninckx, F; Roels, S; Van Cutsem, E | 1 |
| Alqaisi, M; Bernal, P; Bush, D; Byrd, J; Garberoglio, C; Hussein, F; Malik, I | 1 |
| Bekele, BN; Bobustuc, GC; Colman, H; Conrad, CA; Gilbert, MR; Groves, MD; Hsu, SH; Levin, VA; Puduvalli, VK; Qiao, W; Walbert, T; Yung, WK | 1 |
| Foley, EF; Friel, CM; Koc, M; Moskaluk, CA; Rich, TA; Romney, DA; Unger, KR | 1 |
| Arjona-Sánchez, A; Cruz, A; Muñoz, Mdel C; Muntané, J; Padillo, FJ; Perea, MD; Ruiz-Rabelo, J; Túnez, I; Vázquez, R | 1 |
| Chen, G; Kong, LH; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX | 1 |
| Chen, JM; Jin, CH; Li, RX; Liu, XM; Wang, AH; Wang, GP; Xing, LQ | 1 |
| Chan, AP; Chan, SK; Hasan, MR; Jin, C; Kim, J; Kim, YB; Le, ND; Rahman, M; Selvarajan, K; Tai, IT | 1 |
| Chen, WC; Guo, Q; Zhang, DQ; Zhu, JH | 1 |
| Chow, LW; Glück, S; Im, SA; Lee, MH; Ng, TY; Toi, M; Tung, SY; Yip, AY | 1 |
| Guo, HQ; Liu, YY; Yang, SJ; Yao, SN; Yao, ZH; Yuan, YD; Zhao, Y | 1 |
| Akanuma, N; Akutsu, Y; Hanari, N; Hoshino, I; Hu, X; Isozaki, Y; Komatsu-Akimoto, A; Matsubara, H; Mori, M; Mutallip, M; Qin, W; Yusup, G | 1 |
| Jia, Q; Sui, W; Wang, Z; Wu, L; Zhang, W; Zhang, Y | 1 |
| Feng, YG; Gao, ZX; Li, YQ; Liu, WD; Shi, LH; Sun, XE; Sun, XN; Zhang, HM; Zhang, XQ | 1 |
| Ahn, SH; Choi, JJ; Kim, YH; Kwon, SK; Lee, DY; Oh, SM; Park, SW; Shin, ES; Sung, MW | 1 |
| Gotoh, N; Igarashi, K; Karasawa, T; Kato, Y; Kuzumaki, N; Narita, M; Otsuka, M; Sagara, A | 1 |
| Baez-Diaz, L; Bandos, H; Brufsky, AM; Carolla, RL; Fehrenbacher, L; Geyer, CE; Hamm, JT; Jacobs, SA; Julian, TB; Mamounas, EP; Paterson, AHG; Polikoff, J; Provencher, L; Rastogi, P; Robidoux, A; Swain, SM; Ward, PJ; Wolmark, N | 1 |
8 review(s) available for fluorouracil and celecoxib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Recently reported biological activities of pyrazole compounds.
Topics: Analgesics; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Antineoplastic Agents; Antiviral Agents; Humans; Pyrazoles | 2017 |
Synthesis and biological activity of structurally diverse phthalazine derivatives: A systematic review.
Topics: Humans; Phthalazines | 2019 |
Capecitabine and radiation therapy for advanced gastrointestinal malignancies.
Topics: Antineoplastic Agents; Capecitabine; Celecoxib; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Prodrugs; Pyrazoles; Radiation-Sensitizing Agents; Sulfonamides; Treatment Outcome | 2002 |
COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Humans; Isoenzymes; Membrane Proteins; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Radiation-Sensitizing Agents; Stomach Neoplasms; Sulfonamides | 2003 |
Current and ongoing trials with irinotecan in the United States.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Pyrazoles; Sulfonamides | 2003 |
Novel opportunities in the treatment and prevention of scarring.
Topics: Bleomycin; Botulinum Toxins, Type A; Celecoxib; Cicatrix; Fluorouracil; Humans; Immunosuppressive Agents; Laser Therapy; Neuromuscular Agents; Pyrazoles; Sulfonamides; Tacrolimus; Verapamil | 2004 |
First-line therapeutic strategies in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Celecoxib; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Humans; Irinotecan; Leucovorin; Meta-Analysis as Topic; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Treatment Outcome; Vitamin B Complex | 2008 |
27 trial(s) available for fluorouracil and celecoxib
| Article | Year |
|---|---|
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Celecoxib; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Pilot Projects; Pyrazoles; Sulfonamides; Treatment Outcome | 2004 |
Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Celecoxib; Chemotherapy, Adjuvant; Cisplatin; Cyclooxygenase Inhibitors; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Pyrazoles; Radiotherapy, Adjuvant; Sulfonamides; Survival Analysis; Time Factors | 2004 |
A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer.
Topics: Abdominal Pain; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Diarrhea; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Pyrazoles; Sulfonamides | 2005 |
Feasibility of RNA collection for micro-array gene expression analysis in the treatment of cervical carcinoma: a scientific correlate of RTOG C-0128.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Celecoxib; Cisplatin; Combined Modality Therapy; Feasibility Studies; Female; Fluorouracil; Gene Expression Profiling; Humans; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Pyrazoles; RNA; Sulfonamides; Uterine Cervical Neoplasms | 2005 |
FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Celecoxib; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pyrazoles; Sulfonamides; Treatment Outcome | 2005 |
A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Glutamine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pyrazoles; Sulfonamides; Treatment Outcome | 2005 |
Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival?
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Celecoxib; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Pain; Peripheral Nervous System Diseases; Pyrazoles; Retrospective Studies; Sulfonamides; Survival Analysis; Treatment Outcome | 2006 |
FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrazoles; Sulfonamides; Treatment Outcome | 2006 |
Increases in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A | 2006 |
Molecular responses of rectal cancer to preoperative chemoradiation.
Topics: Adult; Aged; Biomarkers, Tumor; Celecoxib; Cyclooxygenase 2; Female; Fluorouracil; Humans; Immunohistochemistry; Interleukin-6; Ki-67 Antigen; Male; Membrane Proteins; Middle Aged; Neoadjuvant Therapy; Osteopontin; Preoperative Care; Prognosis; Pyrazoles; Rectal Neoplasms; Sulfonamides | 2006 |
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrazoles; Sulfonamides; Survival Rate; Treatment Outcome | 2007 |
A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Celecoxib; Cisplatin; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Pyrazoles; Sulfonamides; Survival Analysis | 2007 |
A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Celecoxib; Cisplatin; Combined Modality Therapy; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Pyrazoles; Radiotherapy Dosage; Sulfonamides; Uterine Cervical Neoplasms | 2007 |
Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neoplasms; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluorouracil; Glucuronates; Humans; Intestinal Mucosa; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Mucositis; Neoplasm Transplantation; Neoplasms, Experimental; Pyrazoles; Rats; Rats, Inbred F344; Sulfonamides | 2007 |
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Pyrazoles; Sulfonamides; Survival Analysis; Treatment Failure | 2008 |
Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Celecoxib; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Humans; Middle Aged; Pyrazoles; Sulfonamides; Survival Rate; Treatment Failure; Uterine Cervical Neoplasms | 2007 |
Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study.
Topics: Administration, Oral; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Celecoxib; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; Pyrazoles; Sulfonamides; Treatment Outcome | 2007 |
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Diarrhea; Double-Blind Method; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Prospective Studies; Pulmonary Embolism; Pyrazoles; Shock, Septic; Sulfonamides; Survival Analysis | 2008 |
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Capecitabine; Celecoxib; Combined Modality Therapy; Cyclooxygenase Inhibitors; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Prodrugs; Pyrazoles; Soft Tissue Neoplasms; Sulfonamides; Survival Rate | 2008 |
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Celecoxib; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazoles; Quinazolines; Risk; Sulfonamides | 2008 |
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Carcinoma, Pancreatic Ductal; Celecoxib; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Pyrazoles; Sulfonamides | 2009 |
Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
Topics: Administration, Oral; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Pyrazoles; Sulfonamides; Survival Rate | 2009 |
Double blind randomized phase II study with radiation+5-fluorouracil+/-celecoxib for resectable rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Combined Modality Therapy; Double-Blind Method; Female; Fluorouracil; Follow-Up Studies; Humans; Interleukin-6; Male; Middle Aged; Pyrazoles; Rectal Neoplasms; Sulfonamides | 2009 |
A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Deoxycytidine; Diarrhea; Fecal Incontinence; Female; Fluorouracil; Gangrene; Gastrointestinal Diseases; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Proctitis; Pyrazoles; Radiation Injuries; Radiation-Sensitizing Agents; Rectal Neoplasms; Sulfonamides | 2010 |
Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial.
Topics: Adenocarcinoma; Aged; Algorithms; Antimetabolites, Antineoplastic; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Pyrazoles; Sulfonamides | 2012 |
Observation of curative efficacy and prognosis following combination chemotherapy with celecoxib in the treatment of advanced colorectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2; Demography; Female; Fluorouracil; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Pyrazoles; Sulfonamides; Treatment Outcome | 2011 |
Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Phenobarbital; Prospective Studies; Pyrazoles; Receptor, ErbB-2; Sulfonamides; Taxoids | 2013 |
31 other study(ies) available for fluorouracil and celecoxib
| Article | Year |
|---|---|
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Investigations on cytotoxicity and anti-inflammatory potency of licofelone derivatives.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cyclooxygenase Inhibitors; Edema; Female; Male; Mice; Pyrroles | 2011 |
Stereoselective synthesis and anti-proliferative effects on prostate cancer evaluation of 5-substituted-3,4-diphenylfuran-2-ones.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Furans; Humans; Male; Molecular Structure; Prostatic Neoplasms; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Novel pyrazoline derivatives as bi-inhibitor of COX-2 and B-Raf in treating cervical carcinoma.
Topics: Binding Sites; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Design; Female; HeLa Cells; Humans; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins B-raf; Pyrazoles; Quantitative Structure-Activity Relationship; Sulfonamides; Uterine Cervical Neoplasms | 2014 |
Discovery of novel hybrids of diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Arachidonate 5-Lipoxygenase; Caffeic Acids; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Lipoxygenase Inhibitors; Lung Neoplasms; Molecular Structure; Structure-Activity Relationship; Triazoles | 2016 |
Expanding the anticancer potential of 1,2,3-triazoles via simultaneously targeting Cyclooxygenase-2, 15-lipoxygenase and tumor-associated carbonic anhydrases.
Topics: Antineoplastic Agents; Arachidonate 15-Lipoxygenase; Carbonic Anhydrases; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Molecular Structure; Structure-Activity Relationship; Triazoles | 2020 |
New studies highlight benefit of Xeloda in new combination treatments for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pyrazoles; Sulfonamides | 2002 |
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Deoxycytidine; Female; Fluorouracil; Humans; Hypoxia; Isoenzymes; Male; Membrane Proteins; Middle Aged; Neovascularization, Pathologic; Peripheral Nervous System Diseases; Prodrugs; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Retrospective Studies; Sulfonamides; Syndrome | 2002 |
Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Bleomycin; Blotting, Western; Carcinoma; Celecoxib; Cell Line, Tumor; Cell Survival; Cisplatin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; DNA Fragmentation; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Fluorouracil; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Isoenzymes; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulindac; Time Factors; Vincristine | 2003 |
Treatment with 5-fluorouracil and celecoxib displays synergistic regression of ultraviolet light B-induced skin tumors.
Topics: Administration, Topical; Animals; Antimetabolites, Antineoplastic; Celecoxib; Cell Division; Cyclooxygenase Inhibitors; Dinoprostone; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Mice; Mice, Hairless; Pyrazoles; Skin; Skin Neoplasms; Sulfonamides; Ultraviolet Rays | 2004 |
Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
Topics: 5'-Nucleotidase; Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Celecoxib; Colorectal Neoplasms; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Immunohistochemistry; Intestinal Mucosa; Ki-67 Antigen; Lead; Mice; Mice, Nude; Neoplasm Transplantation; Pancreas; Pancreatic Neoplasms; Pyrazoles; RNA, Messenger; Sulfonamides; Xenograft Model Antitumor Assays | 2005 |
Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Immunohistochemistry; Ki-67 Antigen; Middle Aged; Pyrazoles; Sulfonamides | 2005 |
Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-gamma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Drug Screening Assays, Antitumor; Fluorouracil; Interferon-gamma; Male; Mice; Mice, Inbred BALB C; Mice, Knockout; Neovascularization, Pathologic; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A | 2007 |
Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Fluorouracil; HT29 Cells; Humans; Pyrazoles; Sulfonamides | 2007 |
[Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Fluorouracil; Humans; Lactones; Pyrazoles; Stomach Neoplasms; Sulfonamides; Sulfones | 2007 |
Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capecitabine; Celecoxib; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Glioblastoma; Gliosarcoma; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Pyrazoles; Sulfonamides; Survival Rate; Temozolomide; Thioguanine; Treatment Outcome; Young Adult | 2011 |
Preoperative chemoradiation for rectal cancer using capecitabine and celecoxib correlated with posttreatment assessment of thymidylate synthase and thymidine phosphorylase expression.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Celecoxib; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Pyrazoles; Rectal Neoplasms; Sulfonamides; Survival Rate; Thymidine Phosphorylase; Thymidylate Synthase; Young Adult | 2011 |
Effects of capecitabine and celecoxib in experimental pancreatic cancer.
Topics: Animals; Capecitabine; Celecoxib; Cricetinae; Deoxycytidine; Fluorouracil; Lipid Peroxidation; Lipid Peroxides; Male; Mesocricetus; Nitrosamines; Pancreatic Neoplasms; Pyrazoles; Sulfonamides | 2010 |
Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; Aspirin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Celecoxib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Middle Aged; Pyrazoles; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
Increase of cyclooxygenase-2 inhibition with celecoxib combined with 5-FU enhances tumor cell apoptosis and antitumor efficacy in a subcutaneous implantation tumor model of human colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Celecoxib; Cell Proliferation; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytochromes c; Fluorouracil; HT29 Cells; Humans; Immunoenzyme Techniques; In Situ Nick-End Labeling; Injections, Subcutaneous; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pyrazoles; Sulfonamides; Xenograft Model Antitumor Assays | 2013 |
[Inhibitory effects of celecoxib combined with capecitabine on H22 hepatoma mice and its mechanism].
Topics: Animals; Capecitabine; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Deoxycytidine; Drug Synergism; Fluorouracil; Liver Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Pyrazoles; Sulfonamides; Transcription Factor RelA | 2013 |
A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cell Movement; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dihydrouracil Dehydrogenase (NADP); Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoplasm Invasiveness; Orotate Phosphoribosyltransferase; Prostaglandins; Pyrazoles; Radiation-Sensitizing Agents; RNA, Messenger; Sulfonamides | 2014 |
Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H₂₂ murine hepatocarcinoma model.
Topics: Animals; Antigens, CD34; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Fluorouracil; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Male; MAP Kinase Signaling System; Mice; Microvessels; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrazoles; Random Allocation; Sulfonamides; Vascular Endothelial Growth Factor A | 2014 |
Synergic effect between 5‑fluorouracil and celecoxib on hypoxic gastric cancer cells.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Basic Helix-Loop-Helix Transcription Factors; Celecoxib; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Fluorouracil; Humans; Immunohistochemistry; Neoplasm Proteins; Octamer Transcription Factor-3; Pyrazoles; RNA, Messenger; Stomach Neoplasms; Sulfonamides | 2015 |
Celecoxib enhances the inhibitory effect of 5-FU on human squamous cell carcinoma proliferation by ROS production.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Disease Models, Animal; Drug Interactions; Fluorouracil; Heterografts; Mice; Mice, Nude; Random Allocation; Reactive Oxygen Species; Reference Values; Skin Neoplasms; Statistics, Nonparametric; Survival Rate; Tumor Cells, Cultured | 2017 |
Intrinsic Resistance to 5-Fluorouracil in a Brain Metastatic Variant of Human Breast Cancer Cell Line, MDA-MB-231BR.
Topics: Aniline Compounds; Brain Neoplasms; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression; Humans; Minor Histocompatibility Antigens; NF-kappa B; Nitriles; Protein Interaction Maps; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Messenger; RNA, Small Interfering; Sulfonamides; Sulfones | 2016 |
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Mastectomy | 2022 |